Investor Overview

Investor Overview

Corporate Profile

Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. Y-mAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.

Stock Quote

Minimum 15 minutes delayed. Source:

News Releases

Nov 04, 2024

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

Oct 25, 2024

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

Oct 01, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in October